Literature DB >> 16009676

Risks and benefits of azathioprine therapy.

D P B McGovern1, D P Jewell.   

Abstract

The risk of lymphoma may be increased by about fourfold in patients with inflammatory bowel disease treated with thiopurines. The increased risk could be a result of the medications, the severity of the underlying disease, or a combination of the two.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16009676      PMCID： PMC1774869          DOI： 10.1136/gut.2004.053231

Source DB:  PubMed          Journal:  Gut        ISSN： 0017-5749            Impact factor:   23.059


  6 in total

1.  Azathioprine for maintenance of remission in Crohn's disease: benefits outweigh the risk of lymphoma.

Authors:  J D Lewis; J S Schwartz; G R Lichtenstein
Journal:  Gastroenterology       Date:  2000-06       Impact factor: 22.682

2.  Cancer risk in patients with inflammatory bowel disease: a population-based study.

Authors:  C N Bernstein; J F Blanchard; E Kliewer; A Wajda
Journal:  Cancer       Date:  2001-02-15       Impact factor: 6.860

3.  Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine.

Authors:  A Kandiel; A G Fraser; B I Korelitz; C Brensinger; J D Lewis
Journal:  Gut       Date:  2005-08       Impact factor: 23.059

4.  Risk of lymphoma in inflammatory bowel disease.

Authors:  E V Loftus; W J Tremaine; T M Habermann; W S Harmsen; A R Zinsmeister; W J Sandborn
Journal:  Am J Gastroenterol       Date:  2000-09       Impact factor: 10.864

5.  Smoking and non-Hodgkin's lymphoma: a case-control study in the Rhône-Alpes region of France.

Authors:  Hervé Besson; Philippe Renaudier; Ray M Merrill; Bertrand Coiffier; Catherine Sebban; Jacques Fabry; Christian Trepo; Annie J Sasco
Journal:  Cancer Causes Control       Date:  2003-05       Impact factor: 2.506

6.  Effect of cigarette smoking on recurrence of Crohn's disease.

Authors:  L R Sutherland; S Ramcharan; H Bryant; G Fick
Journal:  Gastroenterology       Date:  1990-05       Impact factor: 22.682
  6 in total
  2 in total

Review 1.  Thiopurine treatment in inflammatory bowel disease: clinical pharmacology and implication of pharmacogenetically guided dosing.

Authors:  Alexander Teml; Elke Schaeffeler; Klaus R Herrlinger; Ulrich Klotz; Matthias Schwab
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 5.577

Review 2.  Thiopurine Drugs in the Treatment of Ulcerative Colitis: Identification of a Novel Deleterious Mutation in TPMT.

Authors:  Pierre-Olivier Harmand; Jérôme Solassol
Journal:  Genes (Basel)       Date:  2020-10-16       Impact factor: 4.096
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.